The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

Ali, Majid; Kamjoo, Marzieh; Thomas, Huw D.; Kyle, Suzanne; Pavlovska, Ivanda; Babur, Muhammed; Telfer, Brian A.; Curtin, Nicola J.; Williams, Kaye J.

oai:pure.atira.dk:publications/5208a3c4-fc95-4d8d-9fad-1f920c9ba350

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice

Authors: Majid Ali
Marzieh Kamjoo
Huw D. Thomas
Suzanne Kyle
Ivanda Pavlovska
Muhammed Babur
Brian A. Telfer
Nicola J. Curtin
Kaye J. Williams
Publication date: December 1, 2011
Publisher
Doi

Abstract

Abstract is not available.

article

Similar works

Full text

The University of Manchester - Institutional Repository

Full text is not available

oai:pure.atira.dk:publ...Last time updated on 2/1/2017

This paper was published in The University of Manchester - Institutional Repository.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.